---
id: esmo-renal-cell-carcinoma-2024
title: "ESMO 2024 Clinical Practice Guidelines: Renal Cell Carcinoma"
short_title: "ESMO RCC 2024"

organization: European Society for Medical Oncology
collaborators: null
country: Global (Europe-led)
url: https://www.esmo.org/guidelines
doi: null
pmid: null
open_access: true

specialty: oncology
guideline_type: clinical-practice
evidence_system: ESMO GRADE
conditions:
  - renal cell carcinoma
  - kidney cancer
  - clear cell RCC
tags:
  - nephrectomy
  - immunotherapy
  - TKI
  - pembrolizumab
  - active surveillance

publication_date: 2024-05-01
previous_version_date: 2022-01-01
status: current
supersedes: null
superseded_by: null

pdf_path: null
has_pdf: false
last_reviewed: 2025-12-26
---

## Scope
2024 ESMO clinical practice guideline update on the diagnosis, staging, and management of renal cell carcinoma (RCC).

## Key Recommendations

### Diagnosis and Staging
- **CT Abdomen/Pelvis with Contrast**: Standard for renal mass characterization.
- **CT Chest**: For staging.
- **MRI**: For indeterminate lesions or IVC involvement.
- **Biopsy**: Consider for metastatic disease, ablation planning, or uncertain diagnosis.

### Localized Disease

#### Small Renal Mass (SRM, <4 cm)
- **Active Surveillance**: May be offered for older patients or those with comorbidities.
- **Nephron-Sparing Surgery (Partial Nephrectomy)**: Preferred when technically feasible.
- **Ablation (Cryoablation, RFA)**: For non-surgical candidates.

#### T1b-T2 (>4 cm, Organ-Confined)
- Partial nephrectomy if feasible; radical nephrectomy if not.

#### T3-T4 (Locally Advanced)
- Radical nephrectomy with or without lymph node dissection.

### Adjuvant Therapy
- **Pembrolizumab**: Adjuvant immunotherapy approved for clear cell RCC with high risk of recurrence after nephrectomy (based on KEYNOTE-564). Consider for eligible patients.

### Metastatic RCC (mRCC)

#### First-Line (Clear Cell, Favorable/Intermediate/Poor Risk)
- **Immunotherapy + TKI Combinations**: Pembrolizumab + axitinib, pembrolizumab + lenvatinib, nivolumab + cabozantinib (all preferred options).
- **Immunotherapy + Immunotherapy**: Ipilimumab + nivolumab (intermediate/poor risk).
- **TKI Monotherapy**: Sunitinib, pazopanib (less preferred, may be suitable for favorable risk or IO-ineligible).

#### Subsequent Lines
- Switch to TKI (cabozantinib, axitinib, tivozanib) or immunotherapy if not used previously.

### Non-Clear Cell RCC
- Limited data; consider sunitinib, cabozantinib, or clinical trial.
